GMP Warning To Sandoz Questions Continued Lot Release; Will FDA Block It?
Executive Summary
FDA's warning letter to Sandoz over violations of good manufacturing practices suggests the agency is taking a stronger, but still measured, tone in its GMP oversight
You may also be interested in...
Sandoz GMP Warning Letter: Is The Problem Documentation, Or Leadership?
Upper management at Novartis and Sandoz are responsible for repeated cGMP violations at three Sandoz plants, FDA suggests. The agency’s warning letter, aimed at three sites in North Amercia, includes what may become new biolerplate instructions on drug shortages.
Sandoz Gets New Global, U.S. CEOs: Will Flat Regional Structure Spark Growth?
Sandoz's new CEO Jeff George is flattening out the firm's global organization to position sales groups closer to customers, and he's hired former Barr CEO Christine Mundkur to shape up the U.S. operation in reforms aimed at returning the world's second largest generics business to strong growth
Sandoz Gets New Global, U.S. CEOs: Will Flat Regional Structure Spark Growth?
Sandoz's new CEO Jeff George is flattening out the firm's global organization to position sales groups closer to customers, and he's hired former Barr CEO Christine Mundkur to shape up the U.S. operation in reforms aimed at returning the world's second largest generics business to strong growth